Attached files
file | filename |
---|---|
EX-99.1 - EX-99.1 - Stoke Therapeutics, Inc. | d895061dex991.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 3, 2020
Stoke Therapeutics, Inc.
(Exact Name of Registrant as Specified in its Charter)
Delaware | 001-38938 | 47-114582 | ||
(State or other jurisdiction of incorporation or organization) |
(Commission File Number) |
(I.R.S. Employer Identification No.) | ||
45 Wiggins Ave Bedford, Massachusetts |
01730 | |||
(Address of principal executive offices) | (Zip Code) |
Registrants telephone number, including area code: (781) 430-8200
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered | ||
Common Stock, $0.0001 par value per share | STOK | Nasdaq Global Select Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07 | Submission of Matters to a Vote of Security Holders. |
On June 3, 2020, Stoke Therapeutics, Inc. (the Company) held its 2020 Annual Meeting of Stockholders (the 2020 Annual Meeting) at which the Companys stockholders (i) elected the two Class I directors identified in the table below, each to serve until the third annual meeting of stockholders following the 2020 Annual Meeting or until a successor has been elected and qualified or until an earlier resignation or removal and (ii) ratified the appointment of KPMG LLP as the Companys independent registered public accounting firm for the fiscal year ending December 31, 2020. Set forth below are the final voting tallies for the Companys 2020 Annual Meeting:
Proposal One Election of Directors
Nominee |
Votes For | Votes Withheld |
Broker Non-Votes |
|||||||||
Adrian R. Krainer |
6,767,791 | 5,020,850 | 18,687,546 | |||||||||
Julie Anne Smith |
11,755,025 | 33,616 | 18,687,546 |
Proposal Two Ratification of Selection of Independent Public Registered Accounting Firm
Votes For |
Votes Against |
Abstentions | ||
20,070,180 | 10,393,868 | 7,688 |
Item 7.01 | Regulation FD |
On June 4, 2020, the Company issued a press release announcing the election of Julie Anne Smith as an independent director of the Company at the 2020 Annual Meeting. Ms. Smith will serve on the Compensation Committee of the Board. A copy of the press release is furnished with this report as Exhibit 99.1. Neither the information in Section 7.01 of this Current Report on Form 8-K nor the information in the press release shall be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act.
Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits
Exhibit Number |
Description | |
99.1 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
STOKE THERAPEUTICS, INC. | ||||
Date: June 4, 2020 |
By: |
/s/ Robin A. Walker | ||
Robin A. Walker | ||||
Senior Vice President, Chief Legal Officer and Chief Compliance Officer |